⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 17 in last 7 days 🍎 Food: 0 in last 7 days 🧸 Products: 113 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 17 in last 7 days 🍎 Food: 0 in last 7 days 🧸 Products: 113 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT June 12, 2026

Uromitexan 400 mg - Ampullen 400 mg (Injektions-/Infusionslösung)

📷 Wikipedia: Mesna · Source
Uromitexan 400 mg - Ampullen 400 mg (Injektions-/Infusionslösung)
📷 Wikipedia: Mesna · Source
Uromitexan 400 mg ampoules (injection/infusion solution) are subject to a parallel export ban due to manufacturing capacity shortages.
⚠️
Shortage ongoing
MESNA is currently in short supply in AT.
📈 Timeline
2 days active so far
June 16, 2026 June 17, 2026

What is this? Uromitexan is a medicine called mesna. It is given by injection or drip to protect the bladder during certain cancer treatments.

What's happening? There is a limited supply of this medicine right now. Factories cannot make enough to meet all needs.

Does this affect me? If you take or need Uromitexan in Austria, you may have trouble getting it.

What should I do? Ask your pharmacist or doctor about other options or how to get your next dose.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
MESNA
Agency-published detail

🚫 Parallel export ban active · ATC: V03AF01 · Reason: Kapazitätsengpässe bei der Herstellung · Marketing authorisation holder: Baxter Healthcare GmbH, Stella-Klein-Löw-Weg 15, 1020 Wien, Österreich · Affected packs: 15 Stück Schachtel, Ampulle [eingeschränkt verfügbar, since 2026-06-12, resupply 2026-07-31]

First published
June 12, 2026
Last refreshed by us
10 hours ago
Severity (as classified)
Medium
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Uromitexan 400 mg - Ampullen 400 mg (Injektions-/Infusionslösung). Uromitexan 400 mg ampoules (injection/infusion solution) are subject to a parallel export ban due to manufacturing capacity shortages.
▸ When was this alert issued?
This alert was issued on June 12, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Medium risk. A medium risk means harm is possible under certain conditions. Read the notice and act on the recommended steps.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.